文献速递肝病

无创纤维化检测在MASLD管理中的应用:革新诊断、进展与消退监测

Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring.
PubMed 文献 · Gut · 2025-09-08

随着resmetirom获美国FDA附条件批准,MASLD治疗可能进入新纪元,需全面理解无创检测(NITs)用于诊断和监测MASLD相关纤维化的优势与局限。本文聚焦F2/F3肝纤维化,总结血清生物标志物、影像方法及其联合应用在MASLD管理中的现状,涵盖诊断与基线分层、纤维化进展监测、肝脏相关临床事件预测及疾病消退、缓解和长期肝脏结局评估。文章比较NITs的优缺点,提出将其整合入临床实践的实用策略,并指出当前应用的主要挑战和未来研究方向。

要点

  • NITs可用于MASLD患者F2/F3纤维化的诊断与基线风险分层。
  • NITs可用于监测纤维化进展、预测肝脏相关临床事件及评估疾病消退与缓解。
  • 未来需在不同种族人群中验证NITs,并探索其动态监测及与多组学、人工智能和个性化风险模型的整合。

核心结论

  • 随着resmetirom获美国FDA附条件批准,MASLD治疗可能进入新纪元,需全面理解NITs诊断和监测MASLD相关纤维化的优势与局限。
  • 未来研究应优先在不同种族人群中验证NITs,并探索NITs在动态监测及与多组学技术、人工智能和个性化风险模型整合中的作用,以提高诊断准确性和治疗规划。

研究设计与样本

  • 本文为综述,聚焦F2/F3肝纤维化,总结血清生物标志物、影像方法及其联合应用在MASLD管理中的当前应用现状。

主要发现

  • NITs应用于诊断与基线分层、监测纤维化进展、预测肝脏相关临床事件,以及评估疾病消退、缓解和长期肝脏相关结局。
  • 文章比较了NITs的优势与局限性,并提出将其整合入临床实践的实用策略。
  • 文章指出了当前应用NITs面临的主要挑战和未来潜在研究方向。

临床怎么用

  • 作者提出将NITs整合入临床实践的实用策略,用于MASLD相关F2/F3纤维化的诊断、基线分层、进展监测、临床事件预测及消退与缓解评估。

局限性

  • 文章指出当前应用NITs面临主要挑战,但未具体列出局限性内容。
  • 作者建议未来研究应优先在不同种族人群中验证NITs,并探索其动态监测及与多组学、人工智能和个性化风险模型的整合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the recent conditional approval of resmetirom by the US Food and Drug Administration, the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) has potentially entered a new era, requiring a comprehensive understanding of the strengths and weaknesses of non-invasive tests (NITs) for diagnosing and monitoring MASLD-related fibrosis. This article focuses on F2/F3 liver fibrosis and summarises the current application status of NITs, including serum biomarkers, imaging methods and their combined use in the management of MASLD. The article highlights the application of NITs in several areas, including diagnosis and baseline stratification, monitoring progression of fibrosis, prediction of liver-related clinical events, as well as assessment of disease regression, remission and long-term liver-related outcomes. Furthermore, we compare the advantages and limitations of NITs and propose practical strategies for integrating them into clinical practice. Additionally, we highlight the main challenges currently faced in the application of these NITs and potential future research avenues. We suggest that future studies prioritise the validation of NITs across diverse ethnic populations. We believe it essential to explore the role of NITs in dynamic monitoring and integration of multiomics technologies, artificial intelligence and personalised risk models to improve diagnostic accuracy and treatment planning.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Feng G, Wong VW, Targher G, et al. Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. Gut. 2025. PMID: 40675797. doi:10.1136/gutjnl-2025-335542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。